Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option
- PMID: 17685384
- DOI: 10.1002/cncr.22940
Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option
Abstract
Depending on initial prognostic factors, an estimated 10%-60% of men who undergo definitive radiation therapy for prostate cancer may experience a biochemical recurrence. Even though hormonal therapy is standard for metastatic recurrences, no consensus exists on optimal salvage therapy for those recurrences thought confined to the prostate. Salvage treatment options for these local recurrences have historically been limited to salvage prostatectomy, hormonal therapy, or cryotherapy. Salvage prostate brachytherapy, however, uses a widely available technique and may provide another option for attaining disease control in patients with localized failures, although only about 110 cases have been reported in the literature. In this report, the authors have described their own series of salvage brachytherapy cases as well as presented a review of other such series reported in the literature. In addition, the authors included a comprehensive review of published experiences with surgery and cryotherapy as salvage options. It appears that salvage brachytherapy, when combined with careful patient selection, is at least as effective as other salvage options with comparable or potentially fewer treatment-related side effects.
Similar articles
-
Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.J Clin Oncol. 2005 Nov 10;23(32):8198-203. doi: 10.1200/JCO.2005.03.1468. J Clin Oncol. 2005. PMID: 16278473 Review.
-
Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.J Urol. 2009 Aug;182(2):517-25; discussion 525-7. doi: 10.1016/j.juro.2009.04.006. Epub 2009 Jun 13. J Urol. 2009. PMID: 19524984
-
Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.Brachytherapy. 2008 Jan-Mar;7(1):17-21. doi: 10.1016/j.brachy.2007.11.002. Epub 2008 Jan 16. Brachytherapy. 2008. PMID: 18201939
-
Management of prostate cancer recurrence after definitive radiation therapy.Cancer Treat Rev. 2010 Apr;36(2):91-100. doi: 10.1016/j.ctrv.2009.06.006. Epub 2010 Jan 25. Cancer Treat Rev. 2010. PMID: 20100637 Review.
-
Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy.BJU Int. 2012 Feb;109 Suppl 1:17-21. doi: 10.1111/j.1464-410X.2011.10826.x. BJU Int. 2012. PMID: 22239225 Review.
Cited by
-
Targeted radiotherapy with gold nanoparticles: current status and future perspectives.Nanomedicine (Lond). 2014 May;9(7):1063-82. doi: 10.2217/nnm.14.55. Nanomedicine (Lond). 2014. PMID: 24978464 Free PMC article. Review.
-
Case Report: Adaptive radiotherapy in the radiation salvage of prostate cancer.Front Oncol. 2022 Aug 15;12:898822. doi: 10.3389/fonc.2022.898822. eCollection 2022. Front Oncol. 2022. PMID: 36046047 Free PMC article.
-
Re-irradiation for salvage of prostate cancer failures after primary radiotherapy.World J Urol. 2013 Dec;31(6):1339-45. doi: 10.1007/s00345-012-0953-7. Epub 2012 Sep 28. World J Urol. 2013. PMID: 23053208 Review.
-
Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.Strahlenther Onkol. 2023 Jun;199(6):554-564. doi: 10.1007/s00066-023-02043-3. Epub 2023 Feb 2. Strahlenther Onkol. 2023. PMID: 36732443 Free PMC article.
-
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer.Endocr Relat Cancer. 2012 Jan 9;19(1):1-12. doi: 10.1530/ERC-11-0072. Print 2012 Feb. Endocr Relat Cancer. 2012. PMID: 21903859 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical